PfAMA1-expressing chimeric rodent malaria parasites provide an in vivo platform for evaluating multistage interventions against malaria
This study establishes a novel in vivo mouse model using CRISPR/Cas9-engineered chimeric rodent malaria parasites expressing *Plasmodium falciparum* AMA1 (and optionally CSP) to functionally validate the essential role of the AMA1-RON2 interaction in host cell invasion and to evaluate multistage, multi-antigen malaria interventions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Malaria remains one of the world's most persistent and deadly diseases, caused by a microscopic parasite that moves between mosquitoes and humans. The parasite has a complex life cycle, starting when an infected mosquito bites a person and injects a form called a sporozoite into the skin. These sporozoites travel to the liver, where they multiply and release a second form, the merozoite, into the bloodstream. It is the merozoites that invade red blood cells, causing the fever and illness associated with the disease. To stop the parasite, scientists have long looked for ways to block its ability to enter human cells. A key player in this invasion is a protein called Apical Membrane Antigen 1, or AMA1. This protein acts like a specialized tool on the surface of the parasite, helping it latch onto and push its way into a host cell. However, creating a vaccine or drug that targets this protein has been difficult because the parasite's version of AMA1 changes its shape slightly from one strain to another, allowing it to evade immune defenses. Furthermore, because the parasite uses this same tool at two different stages of its life—first to enter the liver and later to enter the blood—scientists need a way to test interventions that could stop it at both points.
To solve this problem, a team of researchers created a new kind of laboratory model using a mouse parasite that behaves like the human parasite. They used advanced genetic engineering to swap out the mouse parasite's own version of the AMA1 protein with the version found in the human malaria parasite, Plasmodium falciparum. The result was a hybrid parasite that looks and acts like the mouse parasite but carries the specific human target scientists want to study. The researchers found that this hybrid parasite worked perfectly well in mice, infecting the liver and blood cells just as efficiently as the original mouse parasite. This proved that the human protein could function correctly inside a mouse body, effectively replacing the mouse version. This success meant the hybrid parasite could serve as a safe and practical stand-in for the dangerous human parasite, allowing scientists to test new drugs and antibodies in a living animal without needing to work directly with the human version.
The team then tested whether this new model could be used to block the parasite's entry into cells. They introduced a specific peptide, a short chain of amino acids designed to jam the interaction between the parasite's AMA1 protein and a matching protein on the host cell. When they treated mice infected with the hybrid parasite with this peptide, the parasite's ability to multiply in the blood dropped significantly. Similarly, when they exposed liver cells in a dish to the hybrid parasite along with the peptide, the number of successful infections fell by about ninety percent. These results confirmed that the human protein in the mouse parasite was still using the same invasion mechanism as the real human parasite, and that blocking this mechanism worked in both the liver and blood stages. This demonstrated that the hybrid parasite is a reliable tool for screening new treatments that aim to stop the parasite at multiple points in its life cycle.
Beyond testing drugs, the researchers used the hybrid parasite to see if it could train the immune system to recognize the human parasite. They infected rats with the hybrid parasite and collected their blood to test for antibodies. When these antibodies were added to cultures of the actual human malaria parasite, they significantly slowed down its growth. This suggested that infecting the rats with the hybrid parasite had taught their immune systems to recognize the specific shape of the human protein, creating a defense that worked against different strains of the human parasite. To make the model even more useful, the scientists created a second version of the hybrid parasite that also carried a second human protein, circumsporozoite protein, which is the target of the first approved malaria vaccine. This double-hybrid parasite can now be used to test vaccines or drugs that target two different parts of the parasite's life cycle at the same time.
The work provides a powerful new platform for developing multistage interventions against malaria. By using these genetically engineered rodent parasites, scientists can now evaluate how well new antibodies or small molecules block the parasite's ability to invade cells in a living system. The study showed that the human protein functions correctly in the mouse host, interacts with the mouse cell machinery as expected, and can be targeted by inhibitors that work in both the liver and blood stages. While the researchers noted that the hybrid parasite is a model and not the human disease itself, the results suggest it is a robust and versatile tool. It allows for the rapid testing of ideas that would otherwise be difficult or impossible to study directly in human parasites, offering a clearer path toward finding treatments that can stop malaria before it causes illness and before it spreads.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.